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EDITORIAL
Disease monitoring in chronic obstructive 
pulmonary disease: is there a role for biomarkers?
P.L.M.L. Wielders, P.N.R. Dekhuijzen
Biological or biochemical markers (so-called biomar­
kers) are of potential interest for clinical application to 
monitor chronic diseases. Although biomarkers are fre­
quently used in toxicology and oncology, their appli­
cation in monitoring nonmalignant pulmonary disease 
has been confined to basic research. With the appear­
ance of new noninvasive and less invasive markers it 
is tempting to speculate on their potential role in pati­
ents with chronic obstructive pulmonary disease (COPD).
COPD: current perspective
COPD is known to have major morbidity and mor- 
tality [1], Since the presence and severity of the airflow 
limitation are associated with the prognosis with res­
pect to survival, it is not only important to identify risk 
factors for the development of COPD, but also to pre­
vent worsening of the disease in an early stage, in order 
to alter the natural history, especially in those who will 
have a rapid decline in pulmonary function. In epide­
miological studies, risk factors for a rapid decline are 
marked bronchial hyperresponsiveness, high number of 
pack-years, low value of postbronchodilator forced ex»* 
piratory volume in one second (FEVl) and low reversibil­
ity [2]. An individual estimation of the risk for presence 
or absence of a (future) rapid decline, however, is dif­
ficult to make. Sensitive clinical tools to establish the 
diagnosis at an earlier stage and to monitor the activi­
ty of the disease are not yet available. The present pos­
sibilities for an objective follow-up of patients with 
COPD consist of measurements of lung function at reg­
ular intervals [2]. However, lung function data only 
partially reflect the ongoing pathological process and 
are, therefore, too insensitive to monitor the actual state 
of the disease.
Biomarkers?
The question now arises whether biomarkers will be 
helpful in the identification of these individual risk fac­
tors. Biomarkers include markers of exposure to exter­
nal influences, markers of susceptibility to that specific
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disease and markers of pathophysiological changes rela­
ted to the disease. Biomarkers of exposure are impor­
tant if environmental or biological factors are studied, 
e.g. in case of occupational exposure or follow-up dur­
ing smoking cessation programmes. They are of less 
importance in monitoring disease activity. Ideally, mar­
kers also provide insight into the susceptibility to the 
disease, are well correlated with the actual state of the 
pathological process and reflect the clinical severity of 
the disease. For applicability in respiratory disease, 
these biomarkers should have specific properties, They 
should accurately reflect the changes in disease activ­
ity in the target organ, in this case the lung. This requires 
a high sensitivity and specificity. They should be re­
producible in steady state, easy to obtain, preferably in 
a noninvasive fashion, thereby facilitating repeated 
measurements. They should also reflect the changes due 
to therapy and, finally, be of prognostic significance. A 
biomarker of susceptibility (besides deficiency of a r  
proteinase inhibitor) may reveal why some smokers are 
at risk of developing COPD and others are not. A bio­
marker of effect (other than lung function data) would 
be valuable, e.g. in assessing a rationale for therapeutic 
intervention. Clearly, in COPD there is a need for more 
sensitive markers to follow the course of the disease 
and especially to determine which patients are suscep­
tible for a rapid decline. To determine which biomarkers 
are potentially suitable parameters to be used in COPD, 
clues may be found in the evaluation of the patholog­
ical process.
COPD: inflammation and oxidative stress
Inflammatory processes in the bronchi, bronchioli 
and alveoli and their possible influence on oxidative 
stress are thought to play a crucial role in the devel­
opment of COPD [3—5]. There is an active ongoing in­
flammatory process in both the central airways and the 
parenchyma. The inflammatory processes also influ­
ence the balance between oxidants and antioxidants. An 
increased number of neutrophils and macrophages, and 
an increase in their activity, accounts for an increased 
production of reactive oxygen species (ROS). ROS can 
damage cellular lipid membranes and molecules such as 
proteins and deoxyribonucleic acid (DNA). Intracellu­
lar and extracellular anti-oxidative defence mechanisms 
protect the lung against ROS, in which the glutathione 
redox cycle plays an important role.
Accordingly, biomarkers in COPD should reflect both
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the inflammatory nature and oxidative stress, express 
their relationship to the intensity of the pathological 
process and predict the individual outcome. If a bio­
marker, or a panel of biomarkers, with those properties 
is available, the method of acquisition still remains to 
be determined.
Current biomarkers
Clearly, biomarkers obtained by bronchoscopy are 
not suitable for the clinical follow-up of these patients. 
However, these invasive measures reflect the ongoing 
pathological process and, thus, should provide guidance 
towards development and application of less invasive 
biomarkers. Repeated observations in bronchoalveolar 
lavage (BAL) and biopsies show the significance of 
neutrophil activity in COPD. Increased number of neu­
trophils in BAL and their increased activity [3] is cor­
related with air flow limitation.
In contrast to the invasive procedures, examination of 
(induced) sputum offers several opportunities in COPD. 
Cellular markers, markers of activation and anti-oxi­
dative parameters can be measured, although potential 
changes in biomarkers due to the technique of sputum 
induction itself (e.g. neutrophilia?) may be underesti­
mated, Recently, K e a t in g s  et aL [6] showed increased 
levels of interleukin (IL)-S (recruitment and activation 
of neutrophils) in patients with COPD, compared with 
asthmatics, healthy smokers and nonsmokers. In addi­
tion, myeloperoxidase and human neutrophil lipocalin 
(HNL), both markers of neutrophil activity, were signi­
ficantly higher in COPD patients compared to asthma­
tics and healthy controls [7]. These results suggest that 
markers of neutrophil activation may be more specific 
for COPD than for asthma. These findings are in accor­
dance with findings in BAL, suggesting that induced 
sputum and BAL reflect similar changes, at least in this 
respect. In the same study [6], tumour necrosis factor- 
a  (TNF-a), which acts as an activator of adhesion mol­
ecules on endothelial cells and thereby influences the 
chemotaxis of eosinophils, was elevated in both COPD 
and asthma* This supports the concept that the eosinophil, 
the most prominent cell in asthma, is not without sig­
nificance in COPD, Probably it is not only the number 
of eosinophils, but also their activated state that acco­
unts for this finding. Evidence for this hypothesis was 
provided in another study by the same authors [7], demon­
strating that eosinophilic activation markers were raised 
in induced sputum, both of patients with COPD and 
asthma, whereas the total numbers of eosinophils per 
millilitre were similar [7]. BAL data however, do not 
confirm these observations. Data on anti-oxidative para­
meters (e.g. glutathione) in induced sputum are not yet 
available, but preliminary data from our laboratory in­
dicate an increased concentration of total glutathione in 
induced sputum of patients with smoking-related COPD 
in comparison with healthy controls [8]. In BAL, an in­
verse correlation was found between the predicted value 
of FEVl and the concentration of total glutathione [3], 
The significance of these parameters in induced spu­
tum in relation to the site of disease activity remains to 
be determined.
In the past, several inflammatory parameters have been
studied in blood and urine, but the correlation with the 
pathological process in the target organ, i.e. the lung, 
is weak, except for the markers of eosinophilic acti­
vation. Eosinophilia is associated with a more rapid 
decline in lung function in newly diagnosed chronic 
bronchitis [9]. Monitoring anti-oxidant activity in plas­
ma, however, is more likely to reflect changes in the 
pathological process. Both acute and chronic smoking 
decrease the Trolox equivalent anti-oxidant capacity 
(TEAC) of plasma [10]. TEAC values of patients who 
were admitted to the hospital with exacerbated COPD, 
were lower than those with stable disease and returned 
to similar values at discharge. In spite of that, elevated 
levels of thiobarbituric acid-reactive substances (TBARS) 
in plasma, as a marker of lipid peroxidation, were found 
both in stable and exacerbated COPD [10]. Total glu­
tathione in plasma is another measure of anti-oxidant 
capacity, but its significance is not clear. Whether sys­
temic changes mirror the changes in lung tissue has not 
yet been fully elucidated. Acute exposure to inhaled 
smoke decreases glutathione, whereas in chronic ex­
posure increased levels of glutathione have been found 
in the epithelial lining fluid [11]. This is in contrast to 
findings in plasma, in which no difference was obser­
ved between nonsmokers and smokers [11].
Measurement in exhaled air is a noninvasive proce­
dure, which provides biomarkers of use in clinical appli­
cations . Whereas online measurement of exhaled nitric 
oxide, which reflects the enhanced production in air­
way mucosal inflammation, is increased in asthma, this 
could not be demonstrated in a preliminary study in 
COPD [12]. However, in patients with COPD a higher 
concentration of hydrogen peroxide (mainly produced by 
activated macrophages and neutrophils) in breath con­
densate was found in coriiparison with healthy non- 
smokers, with a further increase in exacerbated COPD
[13]. Although this finding is not specific for COPD
[14], this marker may reflect the intensity of inflam­
mation and oxidative stress in COPD. Elevated levels 
of TBARS in breath condensate, as markers of lipid 
peroxidation, have been demonstrated in asthma [15], 
but not yet in COPD. The influence of various factors 
on the formation of condensate can be avoided with 
online measurement of exhaled gases. Exhaled short- 
chain alkanes (pentane, ethane, ethene) are considered 
to be markers of oxidant-induced lipid peroxidation. 
Indeed, online detected levels of ethane were raised in 
smokers compared to nonsmokers [16]. In a study [17] 
on the effect of supplemental anti-oxidant vitamin on 
ethane levels, a close inverse correlation was found bet­
ween the decline in ethane output and the presupple- 
mental FEYl. The authors concluded that the supplement 
of anti-oxidant vitamins attenuates the smoking-related 
lipid peroxidation and that preserved lung function is 
reflected in ethane output,
From basics to clinical practice?
It is clear that inflammation and oxidative stress are 
closely related to the development and course of COPD. 
Recent developments of biomarkers in research, may 
provide clinical tools which provide earlier and more 
sensitive monitoring than lung function data. Whether
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these markers will be applicable in clinical practice large­
ly depends on the simplicity of measurement, sensiti­
vity, specificity, predictive value and accuracy.
Online measurement of exhaled gases or measure­
ment in breath condensate certainly has this potential 
with respect to the simplicity of sample collection, but 
its role in disease monitoring remains to be investigat­
ed. Markers derived from blood and urine have similar 
properties, but may lack the accurate reflection of chan­
ges in the target organ. Sputum induction, on the other 
hand, at least mirrors changes in the central airways, 
but performance of this test is rather time-consuming 
and strenuous for the patient. Before the definite intro­
duction of several biomarkers to the clinical tool box, 
considerable effort has to be taken to understand some 
of the conflicting data. Therefore, future research should 
be focused on the validation of the different biomark­
ers, i.e. demonstration of their close correlation to the 
pathological process. In addition, search for new accu­
rate biomarkers should be continued, if a real change 
in the natural history of COPD is pursued. Finally, anal­
ogous to the correlation of the births of babies and the 
appearance of the stork in spring, caution should be 
taken not to correlate all kinds of biomarkers, without 
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